Evidence map›Paper›PMID 39438099›Full record

ArticleBMJ open2024

Feasibility of a theory-based intervention towards benzodiazepine deprescribing in Belgian nursing homes: protocol of the END-IT NH cluster-randomised controlled trial.

Perrine Evrard, Tina Chevallereau, Josephine Aikpitanyi, Catherine Pétein, Sandy Tubeuf, Séverine Henrard, Anne Spinewine

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05929443 (Feasibility of a Theory-based Benzodiazepines Deprescribing Intervention in Belgian Nursing Homes), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05929443 naunknown statusnot on this map

Feasibility of a Theory-based Benzodiazepines Deprescribing Intervention in Belgian Nursing Homes: the END-IT Study

TypeinterventionalSponsorUniversité Catholique de LouvainRan2023 to 2024Enrolled80ConditionsBenzodiazepines DeprescribingArmsEND-IT intervention for nursing homes
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Perrine EvrardClinical Pharmacy and Pharmacoepidemiology Research Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium.ORCID 0000-0002-0559-3787
Tina ChevallereauClinical Pharmacy and Pharmacoepidemiology Research Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium.
Josephine AikpitanyiInstitute of Health and Society (IRSS), UCLouvain, Brussels, Belgium.ORCID 0000-0002-6209-137X
Catherine PéteinClinical Pharmacy and Pharmacoepidemiology Research Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium.ORCID 0000-0002-7480-0014
Sandy TubeufInstitute of Health and Society (IRSS), UCLouvain, Brussels, Belgium.
Séverine Henrard *Clinical Pharmacy and Pharmacoepidemiology Research Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium.ORCID 0000-0002-0389-8093
Anne Spinewine *Clinical Pharmacy and Pharmacoepidemiology Research Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium anne.spinewine@uclouvain.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite several calls to deprescribe benzodiazepine receptor agonists (BZRA) in older adults, their use among nursing home residents (NHRs) remains high. Therefore, we developed an intervention targeting general practitioners' and healthcare professionals' behaviours regarding BZRA deprescribing in nursing homes (NHs): The END-IT NH (bENzodiazepines Deprescribing InTerventions Nursing homes) 6-component intervention. Before moving on to a large-scale effectiveness and cost-effectiveness evaluation, this feasibility study aims at: (1) assessing the feasibility of the intervention implementation in NHs, (2) assessing the feasibility of conducting a larger-scale evaluation, in terms of recruitment and data collection and (3) conducting an exploratory cost-effectiveness evaluation. METHODS AND ANALYSIS: We will conduct a cluster-randomised controlled trial in a sample of 6 NHs, with 10-15 NHRs included per NHs. Four NHs will be randomised into the intervention group, and two NHs will deliver usual care (control group). Data collection will occur at baseline, 3, and 6 months (study end). We will collect information to explore implementation fidelity, mechanisms of impact and contextual factors at patient-level, NH-level and healthcare professional-level, using both quantitative and qualitative measures. The feasibility of the study conduction will be assessed by measuring recruitment and attrition rates and completeness of data collection. An exploratory cost-effectiveness evaluation will be conducted based on quality of life and healthcare use and cost data. ETHICS AND DISSEMINATION: This study protocol received approval from the ethical committee of CHU UCL Namur on the 20 June 2023. All data are confidential and will be anonymised prior to analysis. De-identified data will be shared on a data depository with a 2-year embargo. The results of the study will be disseminated through a scientific paper and will be communicated to local stakeholders and policymakers through a local symposium. TRIAL REGISTRATION NUMBER: NCT05929443.

Indexed as

BenzodiazepinesCost-Benefit AnalysisDeprescriptionsFeasibility StudiesNursing HomesRandomized Controlled Trials as TopicAgedBelgiumHomes for the AgedHumansQuality of LifeBenzodiazepinesAgedDrug UtilizationFeasibility StudiesImplementation ScienceQuality Improvement

Identifiers

PMID39438099
PMCPMC11499836

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.